| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
54,455 |
51,906 |
$2.80M |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
10,968 |
10,954 |
$774K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
10,466 |
10,456 |
$726K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
8,577 |
8,430 |
$596K |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
26,652 |
26,583 |
$583K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
8,712 |
8,518 |
$499K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
6,576 |
6,567 |
$472K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
6,230 |
6,169 |
$469K |
| S0302 |
Completed early periodic screening diagnosis and treatment (epsdt) service (list in addition to code for appropriate evaluation and management service) |
46,768 |
46,388 |
$441K |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
39,386 |
38,540 |
$402K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
4,641 |
4,597 |
$372K |
| 87634 |
|
4,659 |
4,615 |
$291K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
5,147 |
5,099 |
$129K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
8,252 |
8,148 |
$109K |
| 90461 |
|
6,110 |
6,099 |
$94K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
4,362 |
4,356 |
$75K |
| 83655 |
|
6,617 |
6,596 |
$74K |
| 99050 |
|
5,123 |
5,088 |
$70K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
1,036 |
1,025 |
$53K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
1,213 |
1,196 |
$52K |
| 99188 |
|
1,836 |
1,835 |
$49K |
| 99173 |
|
3,758 |
3,753 |
$49K |
| 96127 |
|
5,864 |
4,476 |
$47K |
| 87081 |
|
5,671 |
5,616 |
$35K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
2,390 |
1,194 |
$30K |
| 85018 |
|
8,350 |
8,336 |
$18K |
| 92552 |
|
701 |
698 |
$18K |
| 95004 |
Percutaneous tests with allergenic extracts, immediate type reaction |
206 |
203 |
$17K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
403 |
401 |
$17K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
508 |
508 |
$15K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
496 |
496 |
$15K |
| 99401 |
|
411 |
408 |
$9K |
| 0072A |
|
81 |
81 |
$4K |
| 0071A |
|
64 |
64 |
$3K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
21 |
21 |
$3K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
43 |
43 |
$2K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
39 |
39 |
$1K |
| 83718 |
|
122 |
119 |
$926.86 |
| 94760 |
|
208 |
189 |
$502.24 |
| 82465 |
|
122 |
119 |
$488.30 |
| 87807 |
|
32 |
32 |
$350.08 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
18 |
16 |
$280.10 |
| 98966 |
|
18 |
17 |
$193.86 |
| 99174 |
|
307 |
306 |
$167.70 |
| 99441 |
|
12 |
12 |
$129.24 |
| 95117 |
|
16 |
12 |
$94.10 |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
12 |
12 |
$93.08 |
| 81003 |
|
26 |
25 |
$56.68 |
| 96160 |
|
118 |
118 |
$8.56 |
| J7620 |
Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme |
16 |
16 |
$2.21 |
| G2211 |
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) |
130 |
119 |
$0.00 |
| 99072 |
|
472 |
456 |
$0.00 |
| 36416 |
|
990 |
967 |
$0.00 |